摘要
目的:分析卡瑞利珠单抗联合调强放疗在晚期食管鳞癌患者中的治疗效果。方法:选取2020年1月—2022年1月本院诊治的74例晚期食管鳞癌患者,按随机数字表法分为两组,各37例。对照组采用调强放疗[确定大体肿瘤区(GTV)、临床靶体积(CTV)、计划靶体积(PTV),以医用直线加速器进行放疗],观察组加用卡瑞利珠单抗治疗(静脉滴注,200 mg/次,1次/2周),连续治疗6周。比较两组临床疗效、血清肿瘤标志物、免疫状态、短期生存率。结果:观察组客观缓解率高于对照组,有统计学差异(P<0.05);治疗前,两组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)、CD3^(+)、CD4^(+)、CD8^(+)比较,无统计学差异(P>0.05);治疗后,两组CEA、CA125、CA153和CD8^(+)均低于治疗前,CD3^(+)和CD4^(+)均高于治疗前,且观察组CEA、CA125、CA153和CD8^(+)低于对照组,CD3^(+)和CD4^(+)高于对照组,有统计学差异(P<0.05);观察组短期生存率略高于对照组,但无统计学差异(P>0.05);经Logistic回归分析显示,治疗方式对治疗后CEA、CA125和CD8^(+)有影响(OR>1,P<0.05)。结论:卡瑞利珠单抗联合调强放疗在晚期食管鳞癌患者治疗中效果显著,可有效降低机体肿瘤标志物水平,改善免疫状态,一定程度上提高短期生存率。
Objective:To analyze the therapeutic effect of camrelizumab combined with intensity-modulated radiotherapy(IMRT)in patients with advanced esophageal squamous cell carcinoma(ESCC).Methods:74 patients with advanced esophageal squamous cell carcinoma treated at our hospital from January 2020 to January 2022 were selected and randomly divided into two groups,with 37 patients in each group.The control group received intensity-modulated radiation therapy using a medical linear accelerator[to determine the gross tumor area(GTV),clinical target volume(CTV),and planned target volume(PTV)],whereas the observation group received additional treatment with carolizumab(intravenous infusion,200 mg/dose,1 dose/2 weeks)for 6 consecutive weeks.Clinical efficacy,serum tumor markers,immune status,and short-term survival rates were compared between the two groups.Results:The objective remission rate in the observation group was significantly higher than that in the control group(P<0.05).Before treatment,there was no statistically significant difference between the two groups in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen125(CA125),carbohydrate antigen 153(CA153),CD3^(+),CD4^(+),and CD8^(+)(P>0.05).After treatment,CEA,CA125,CA153,and CD8^(+)levels in both groups were lower than those before treatment,while CD3^(+)and CD4^(+)levels were higher than those before treatment.In addition,CEA,CA125,CA153,and CD8^(+)levels in the observation group were lower than those in the control group,whereas CD3^(+)and CD4^(+)levels were higher in the observation group than in the control group(P<0.05).The short-term survival rate of the observation group was slightly higher than that of the control group;however,the difference was not statistically significant(P>0.05).Logistic regression analysis showed that the treatment methods had an impact on post-treatment CEA,CA125,and CD8^(+)(OR>1,P<0.05).Conclusion:The combination of camrelizumab and IMRT is effective in the treatment of patients with advanced esophageal squamous cell carci
作者
李晓静
丁金泉
赖剑平
陈小妹
Li Xiaojing;Ding Jinquan;Lai Jianping;Chen Xiaome(Ganzhou Cancer Hospital Ganzhou,Jiangxi 341000)
出处
《天津药学》
2024年第2期51-54,共4页
Tianjin Pharmacy
关键词
晚期食管鳞癌
卡瑞利珠单抗
调强放疗
免疫状态
生存率
advanced esophageal squamous cell carcinoma
camrelizumab
intensity modulated radiation therapy
immune status
survival rate
